Abstract Historically, 3, 4-dihydroxyphenylalanine (DOPA) has been considered to be an
inert amino acid that alleviates the symptoms of Parkinson's disease by its conversion to …

Historically, 3, 4-dihydroxyphenylalanine (DOPA) has been believed to be an inert amino
acid that alleviates the symptoms of Parkinson's disease by its conversion to dopamine via …

Oa1 is the casual gene for ocular albinism-1 in humans. The gene product OA1, alternatively
designated as GPR143, belongs to G-protein coupled receptors. It has been reported that …

Abstract l-3, 4-Dihydroxyphenylalanine (DOPA) is the metabolic precursor of dopamine, and
the single most effective agent in the treatment of Parkinson's disease. One problem with …

Abstract l-3, 4-Dihydroxyphenylalanine (DOPA) has been believed to be a precursor of
dopamine, and itself being an inert amino acid. Previously, we have proposed DOPA as a …

Parkinson's disease (PD) patients exhibit motor and non-motor symptoms that severely
affect quality of life. Cognitive alterations in PD subjects have been related to both structural …

Electrophysiological studies were performed to determine whether or not hippocampal
serotonergic modulation was affected following repeated administration of …

Brain ischemic insult causes glutamate release and resultant neuronal cell death. We here
show that l-3, 4-dihydroxyphenylalanine (DOPA) is a positive regulatory factor for glutamate …

To establish the neurotransmitter role (s) of L-3, 4-dihydroxyphenylalanine (DOPA) in its own
right, we attempted to clarify whether ip injection of a DOPA antagonist, DOPA cyclohexyl …

Since the 1950s [1, 2], exogenously applied L-3, 4-dihydroxyphenylalanine (levodopa) has
been generally thought to be an inert amino acid that alleviates the symptoms of Parkinson's …